false
Catalog
Medication Management in Early Psychosis and At-ri ...
Presentation Slides
Presentation Slides
Back to course
Pdf Summary
This document is a summary of a webinar on the topic of medications in early psychosis. The webinar was part of the Clinical Support System for Serious Mental Illness (CSS-SMI) initiative implemented by the American Psychiatric Association (APA). The speaker, Dr. Jacob S. Ballon, discussed various aspects related to the use of medications in early psychosis.<br /><br />The webinar highlighted the importance of working with families and establishing goals in the treatment of early psychosis. Dr. Ballon emphasized the need to establish partnerships, manage dissent or difference of opinion, and address stigma. He also discussed the use of medications in individuals at clinical high risk for psychosis, including common categories of medications and considerations for choosing an initial medication.<br /><br />According to the speaker, the APA treatment guidelines for early psychosis are still pending final release. However, he provided some insights into medication choices based on family history, side effects, and meta-analysis studies. He also discussed the impact of race and ethnicity on medication use, dosing strategies, adherence, and the conversation around long-term medication use.<br /><br />The webinar touched on other topics such as long-acting injectables, the use of clozapine, and emerging medications in the pipeline. Dr. Ballon also highlighted the importance of considering metabolic side effects, neurological side effects, and adjunctive medications for symptoms and side effects.<br /><br />In conclusion, the webinar provided valuable information on the use of medications in early psychosis, including considerations for treatment, medication choices, and management of side effects. It emphasized the importance of a comprehensive and individualized approach to medication management in early psychosis.
Keywords
medications
early psychosis
Clinical Support System for Serious Mental Illness
APA
treatment
partnerships
side effects
race
dosing strategies
medication management
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
×
Please select your language
1
English